These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 18689009)
1. [The use of memotropil for treatment of mild cognitive impairment in out-patients with progressive chronic cerebrovascular disorders]. Batysheva TT; Bagir' LV; Kostenko EV; Artemova IIu; Bdovichenko TV; Gazhula PA; Zhuravleva EIu; Ismailov AM; Lisenker LN; Nesterova OV; Otcheskaia OV; Rotor LD; Khozova AA; Boĭko AN Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(1):40-44. PubMed ID: 18689009 [No Abstract] [Full Text] [Related]
2. Experience of the out-patient use of memotropil in the treatment of cognitive disorders in patients with chronic progressive cerebrovascular disorders. Batysheva TT; Bagir' LV; Kostenko EV; Artemova IY; Vdovichenko TV; Ganzhula PA; Zhuravleva EY; Ismailov AM; Lisenker LN; Nesterova OV; Otcheskaya OV; Rotor LD; Khozova AA; Boiko AN Neurosci Behav Physiol; 2009 Feb; 39(2):193-7. PubMed ID: 19140003 [No Abstract] [Full Text] [Related]
3. [The use of lucetam for improvement of cognitive functions in chronic cerebrovascular insufficiency (clinical and encephalographic study)]. Bugrova SG; Novikov AE Zh Nevrol Psikhiatr Im S S Korsakova; 2007; 107(4):44-8. PubMed ID: 18379503 [TBL] [Abstract][Full Text] [Related]
4. [A comparative study of noopept and piracetam in the treatment of mild and moderate cognitive impairment in patients with organic brain diseases of vascular and traumatic origin]. Neznamov GG; Teleshova ES Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(3):33-42. PubMed ID: 18697252 [No Abstract] [Full Text] [Related]
5. The NeuroAiD II (MLC901) in vascular cognitive impairment study (NEURITES). Chen CL; Ikram K; Anqi Q; Yin WT; Chen A; Venketasubramanian N; Cerebrovasc Dis; 2013; 35 Suppl 1():23-9. PubMed ID: 23548916 [TBL] [Abstract][Full Text] [Related]
6. Effect of piracetam on cognitive performance in patients undergoing bypass surgery. Uebelhack R; Vohs K; Zytowski M; Schewe HJ; Koch C; Konertz W Pharmacopsychiatry; 2003 May; 36(3):89-93. PubMed ID: 12806565 [TBL] [Abstract][Full Text] [Related]
7. Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin. Neznamov GG; Teleshova ES Neurosci Behav Physiol; 2009 Mar; 39(3):311-21. PubMed ID: 19234797 [No Abstract] [Full Text] [Related]
8. Different cognitive profiles between mild cognitive impairment due to cerebral small vessel disease and mild cognitive impairment of Alzheimer's disease origin. Zhou A; Jia J J Int Neuropsychol Soc; 2009 Nov; 15(6):898-905. PubMed ID: 19891819 [TBL] [Abstract][Full Text] [Related]
9. Assessment of aphasia in relation to communication and cognitive impairments among stroke patients. Sundet K Scand J Rehabil Med Suppl; 1992; 26():60-9. PubMed ID: 1488641 [TBL] [Abstract][Full Text] [Related]
10. Subcortical vascular cognitive impairment, no dementia: EEG global power independently predicts vascular impairment and brain symmetry index reflects severity of cognitive decline. Sheorajpanday RV; Mariën P; Nagels G; Weeren AJ; Saerens J; van Putten MJ; De Deyn PP J Clin Neurophysiol; 2014 Oct; 31(5):422-8. PubMed ID: 25271680 [TBL] [Abstract][Full Text] [Related]
11. [The effect of cerebrolysin on moderate cognitive impairment in cerebral vascular insufficiency (a clinical and electrophysiological study)]. Damulin IV; Koberskaia NN; Mkhitarian EA Zh Nevrol Psikhiatr Im S S Korsakova; 2007; 107(5):32-8. PubMed ID: 18379494 [TBL] [Abstract][Full Text] [Related]
12. Montreal cognitive assessment and analysis of related factors for cognitive impairment in patients with chronic cerebral circulation insufficiency. Zhang L; Dong W; Han J; Wang Z; Sun D; Ji X; Li M; Zhang B Int J Psychiatry Med; 2015; 50(3):257-70. PubMed ID: 26561273 [TBL] [Abstract][Full Text] [Related]
18. Vascular risk factors do not contribute to motor and cognitive impairment in Parkinson's disease. Sławek J; Wieczorek D; Derejko M; Dubaniewicz M; Brockhuis B; Sitek E; Wilczewska L; Roszmann A; Lass P Parkinsonism Relat Disord; 2010 Jan; 16(1):73-4; author reply 75-6. PubMed ID: 19682944 [No Abstract] [Full Text] [Related]
19. The Florence VAS-COG clinic: a model for the care of patients with cognitive and behavioral disturbances consequent to cerebrovascular diseases. Poggesi A; Salvadori E; Valenti R; Nannucci S; Ciolli L; Pescini F; Pasi M; Fierini F; Donnini I; Marini S; Chiti G; Rinnoci V; Inzitari D; Pantoni L J Alzheimers Dis; 2014; 42 Suppl 4():S453-61. PubMed ID: 25114087 [TBL] [Abstract][Full Text] [Related]
20. Effects of rivastigmine on motor and cognitive impairment in Huntington's disease. de Tommaso M; Specchio N; Sciruicchio V; Difruscolo O; Specchio LM Mov Disord; 2004 Dec; 19(12):1516-8. PubMed ID: 15390067 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]